190
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Reasons for use and experiences of using phenibut, a mixed methods analysis of online reports

ORCID Icon, ORCID Icon, , ORCID Icon &
Pages 458-469 | Received 30 Oct 2022, Accepted 15 Apr 2023, Published online: 15 May 2023

References

  • Khaunina RA. Effect of beta-phenyl-gamma-aminobutyric acid on the central action of pharmacological preparations. Farmakol Toksikol. 1964 Jul-Aug;27:399–403.
  • Khaunina RA. Tranquilizing effects of beta-phenyl-gamma-aminobutyric acid (Fenigam). Biulleten’ eksperimental’noi biologii i meditsiny. 1964 Jan;57:54–58. doi:10.1007/BF00783474.
  • Irie T, Yamazaki D, Kikura-Hanajiri R. F-phenibut (β-(4-Fluorophenyl)-GABA), a potent GABA(B) receptor agonist, activates an outward-rectifying K(+) current and suppresses the generation of action potentials in mouse cerebellar Purkinje cells. Eur J Pharmacol. 2020 Oct 5;884:173437. doi:10.1016/j.ejphar.2020.173437.
  • Kupats E, Vrublevska J, Zvejniece B, Vavers E, Stelfa G, Zvejniece L, Dambrova M. Safety and tolerability of the anxiolytic and nootropic drug phenibut: a systematic review of clinical trials and case reports. Pharmacopsychiatry. 2020 Sep;53:201–08. doi:10.1055/a-1151-5017.
  • Taylor CP, Harris EW. Analgesia with gabapentin and pregabalin may involve N-Methyl-d-aspartate receptors, neurexins, and thrombospondins. J Pharmacol Exp Ther. 2020 Jul;374:161–74. doi:10.1124/jpet.120.266056.
  • Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15;168:107966. doi:10.1016/j.neuropharm.2020.107966.
  • Thorpe AJ, Offord J. The alpha2-delta protein: an auxiliary subunit of voltage-dependent calcium channels as a recognized drug target. Curr Opin Invest Drugs. 2010 Jul;11:761–70.
  • Greenblatt HK, Greenblatt DJ. Gabapentin and pregabalin for the treatment of anxiety disorders. Clin Pharmacol Drug Dev. 2018 Mar;7:228–32. doi:10.1002/cpdd.446.
  • Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001 Winter;7:471–81. doi:10.1111/j.1527-3458.2001.tb00211.x
  • United States Food and Drug Administration. FDA acts on dietary supplements containing DMHA and phenibut 2019. 2021 Oct 18 [accessed 2019 Apr 29]. https://www.fda.gov/food/cfsan-constituent-updates/fda-acts-dietary-supplements-containing-dmha-and-phenibut.
  • Graves JM, Dilley J, Kubsad S, Liebelt E. Notes from the field: phenibut exposures reported to poison centers — United States, 2009–2019. MMWR Morb Mortal Wkly Rep. 2020 Sep 4;69:1227–28. doi:10.15585/mmwr.mm6935a5.
  • Wong A, Little M, Caldicott D, Easton C, Andres D, Greene SL. Analytically confirmed recreational use of Phenibut (β-phenyl-γ-aminobutyric acid) bought over the internet. Clin Toxicol (Phila). 2015;53:783–84. doi:10.3109/15563650.2015.1059944.
  • Owen DR, Wood DM, Archer JR, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev. 2015 Sep;35:591–96. doi:10.1111/dar.12356.
  • Hägg S, Jönsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Safety. 2020 Dec;43:1235–54. doi:10.1007/s40264-020-00985-6.
  • Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2020 Nov 19;81:125–56. doi:10.1007/s40265-020-01432-7.
  • Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food and Drug Administration Adverse Events Reporting System (FAERS). Res Soc Administrative Pharm RSAP. 2019 Aug;15:953–58. doi:10.1016/j.sapharm.2018.06.018.
  • Erowid. Erowid: documenting the complex relationship between humans & psychoactives. [accessed 2020 Dec 14]. https://erowid.org/.
  • Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62:107–15. doi:10.1111/j.1365-2648.2007.04569.x.
  • Dunne S, Shannon B, Dunne C, Cullen W. Patient perceptions of generic medicines: a mixed-methods study. Patient - Patient-Centered Outcomes Res. 2014 Jun 1;7:177–85. doi:10.1007/s40271-013-0042-z.
  • Lotarski SM, Donevan S, El-Kattan A, Osgood S, Poe J, Taylor CP, Offord J. Anxiolytic-like activity of pregabalin in the Vogel conflict test in α2δ-1 (R217A) and α2δ-2 (R279A) mouse mutants. J Pharmacol Exp Ther. 2011 Aug;338:615–21. doi:10.1124/jpet.111.180976.
  • Zvejniece L, Vavers E, Svalbe B, Veinberg G, Rizhanova K, Liepins V, Kalvinsh I, Dambrova M. R-phenibut binds to the α2–δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol Biochem Behav. 2015 Oct;137:23–29. doi:10.1016/j.pbb.2015.07.014.
  • Domon Y, Arakawa N, Inoue T, Matsuda F., Takahashi M., Yamamura N., Kai K., Kitano Y. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365:573–82. doi:10.1124/jpet.117.247551.
  • Felice D, Cryan JF, O’Leary OF. GABA(B) receptors: anxiety and mood disorders. Curr Top Behav Neurosci. 2022 ;52:241–65.
  • Carai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, et al. Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid. Eur J Pharmacol. 2001 Oct 12;428:315–21. doi:10.1016/S0014-2999(01)01334-6.
  • Agabio R, Preti A, Gessa GL. Efficacy and tolerability of baclofen in substance use disorders: a systematic review. Eur Addict Res. 2013;19:325–45. doi:10.1159/000347055.
  • Shukla L, Kandasamy A, Kesavan M, Benegal V. Baclofen in the short-term maintenance treatment of benzodiazepine dependence. J Neurosci Rural Pract. 2014 Nov;5:S53–4. doi:10.4103/0976-3147.145203.
  • Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: a comprehensive literature review and illustrative case report. Bosnian J Basic Med Sci. 2019 May 20;19:125–29. doi:10.17305/bjbms.2018.4008.
  • Jouney EA. Phenibut (β-Phenyl-γ-Aminobutyric Acid): an easily obtainable “Dietary supplement” with propensities for physical dependence and addiction. Curr Psychiatry Rep. 2019 Mar 9;21:23. doi:10.1007/s11920-019-1009-0.
  • Romito JW, Turner ER, Rosener JA, Coldiron L, Udipi A, Nohrn L, Tausiani J, Romito BT. Baclofen therapeutics, toxicity, and withdrawal: a narrative review. SAGE Open Med. 2021;9:20503121211022197. doi:10.1177/20503121211022197
  • Leo RJ, Baer D. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies. Psychosomatics. 2005 Nov-Dec;46:503–07. doi:10.1176/appi.psy.46.6.503.
  • Diagnostic and statistical manual of mental disorders : DSM-5. Arlington, VA: American Psychiatric Association; 2013. ( American Psychiatric A, American Psychiatric Association DSMTF, editors.)
  • Singh J. Time trends in hospitalizations with anxiolytic, sedative, or hypnotic drug use disorder: a 17-year U.S. National Study. J Addict Dis. 2021 Apr 22;40:1–13. doi:10.1080/10550887.2021.1911563.
  • McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med. 2019 Nov;37:2066–71. doi:10.1016/j.ajem.2019.02.044.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.